Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
about
Patient considerations in the management of menopausal symptoms: role of conjugated estrogens with bazedoxifeneThe Recent Review of the Genitourinary Syndrome of MenopauseThe Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the RiskClinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophyOspemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidenceOspemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data.A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapyManagement of Vaginal Atrophy: Implications from the REVIVE Survey.Advances in pharmacotherapy for treating female sexual dysfunction.Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopauseEndometrial safety of ospemifene: results of the phase 2/3 clinical development program.Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophyTreatment of the genitourinary syndrome of menopause.An update on drugs for the treatment of menopausal symptoms.Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophyA biopsychosocial approach to women's sexual function and dysfunction at midlife: A narrative review.Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo.Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.Sexual health as a survivorship issue for female cancer survivors.Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy.The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy.Profile of ospemifene in the breast.Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause.Treatment of vaginal atrophy.Ospemifene in the treatment of vulvovaginal atrophy.A practitioner's toolkit for managing the menopause.Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.Perceptions of dyspareunia in postmenopausal women with vulvar and vaginal atrophy: findings from the REVIVE survey.Emerging hormonal treatments for menopausal symptoms.Selective estrogen receptor modulators in clinical practice: a safety overview.Oestrogen replacement in postmenopausal women.The urogenital system and the menopause.Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study.Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy.Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
P2860
Q26751149-276C11C2-C8B1-4FE4-8180-EC6137A66BEFQ26781733-665FABC2-C4C4-45DC-8F52-D96499386F70Q26821782-226DD4C3-A04E-416D-8F0A-1B39C3678ABFQ28066699-22C83882-336B-4752-9B71-434EF95FC0C4Q30277966-EFEDFE00-6404-40CD-B308-0CBA615398DBQ30380010-E8177E04-A516-4B2B-9731-55C91F4AC38CQ30491704-2300B32A-69DA-442E-91E6-DC5DF316828AQ33605919-4CF6705A-ACD3-4CA2-B0FE-B8C1F950811FQ33809618-2015C535-B947-48E1-AE4E-1E56B4AADC90Q34465301-971EF07A-74CE-4A44-A260-259C26A02677Q34490225-39101BAA-1468-41D5-82C7-AA1E5A0F64DEQ34532021-76090D4C-BEA6-4326-A8E1-4602F92689DBQ34759968-B56EBFC5-CDE5-40EF-868E-EB45B196FBA3Q35317535-A4D46039-13EC-443A-83FD-6EA61AE33240Q35626394-79D8DFD3-52B4-49E3-8ABE-33A3833984D3Q35772318-02964B11-8681-414F-8CF3-179EF671A1CCQ35784054-5DC95CAC-389C-4653-BA8F-967DDB89AE11Q35824414-3D2AA094-DC69-4687-977E-25466E10C82DQ36482360-DBA53109-5778-44AF-8E91-F52A9B4A8638Q36730209-14B7FFEC-10D5-49BD-A342-ADB7E8810A6DQ37091899-0FD57EBF-1B7D-4C46-86DB-21696211B207Q37221035-87FD8389-83DF-45D7-A0FD-3A22D3F11C96Q37589056-417641F3-34AE-4F0D-A00F-36A08244EB5BQ37677579-58F3EF69-0CB7-436D-B704-98E136F6E662Q37722587-230FDA1D-BEE7-4076-9350-40F69EBC28E9Q38129004-8ADFFEC7-DA6F-49A3-8F51-A511B373BA46Q38178431-66BCEA0B-94C3-44D7-B361-109FCF71DEB0Q38193877-23D5091A-FFF4-46FB-ADA0-5BF8F81A78CAQ38194966-BD7BEBBE-F8C0-4EEA-8B5E-5801CC3C907DQ38226731-B4655762-4F7C-4EC4-AE5D-775A0A6CAE06Q38232774-3EDEB78B-4ED2-4F25-BBBA-D979AAE4A3FBQ38254653-43ADF697-65AA-4FCC-BD75-F0B519B1B12DQ38307019-68CF8BE0-AF85-4F7C-9545-051FDB41FE35Q38455538-5E3C618E-767C-440A-9CF0-B19CF3D09CF2Q38526762-A2FDC4A8-5275-4584-B046-E0A36B5713AAQ38586317-27D89D77-10E9-488F-AEE3-25B52BD94183Q38836000-54FC7E69-D9FD-4447-BBBB-445F28A2CAB9Q41110474-4F63F276-CE2D-4972-A47A-CD34C2A48A6AQ41689276-40889C13-925B-494B-A4B1-32B77B546180Q45070875-3DB6743C-D0CE-455C-BA06-22E2E7530F75
P2860
Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@ast
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@en
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@nl
type
label
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@ast
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@en
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@nl
prefLabel
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@ast
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@en
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@nl
P2093
P1433
P1476
Ospemifene, a novel selective ...... al vulvar and vaginal atrophy.
@en
P2093
David J Portman
Gloria A Bachmann
James A Simon
Ospemifene Study Group
P304
P356
10.1097/GME.0B013E318279BA64
P407
P577
2013-06-01T00:00:00Z